2026 H1 -tulosraportti
UUTTA
Tänään
‧45 min
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·5 t sitten · MuokattuYes, the market showed where things stand today. As I wrote today before open. It will be red. 11.5 % down indicates that some big players took profit. Some support levels broke down today. Selling pressure was high today. Unfortunately, management didn't have much to offer. Thor must deliver concrete, quantified new large contracts. No input on growth and how the Alpha One factory is functioning. It seemed between the lines that it had slowed down a bit. Management itself says it will generate revenue just under kr 180 million next year. Then it obviously takes far too long to produce Th 228. The market has also reacted to this. The ship MS Thor must get on track and gain more momentum. They should scale up much faster. Then they will get applause from the crew. Thor must switch to faster engines. 💪
·6 t sittenReported 6 flat yesterday. Too bad to see I missed by one øre. Ready to go up again to 7 during next week :-)
Conclusion from today's H1: : The earnings presentation confirms that Thor has succeeded with the critical step from pilot to industrial production. This is a solid operational result in a company that is still in an early commercialization phase. Current financial figures are weak (as expected since before startup), and the focus going forward will be on actual volume ramp-up, deliveries and cash flow towards break-even in 2027. For investors with high risk appetite within medicine, this is a positive step, but the stock will likely remain volatile until revenues become more visible.
·7 t sittenIt's important to note that much of the biotech sector is down today. Not only Thor. Short-term noise.
6 t sittenThe Pb-212 market is one of the fastest-growing segments in the entire radiopharmaceutical industry. It is growing at a CAGR of 21.45%, with the market projected to rise from $218 million to $851 million by 2032. Growth is driven by the expansion of TAT therapies, the scaling of Th-228 generators, and strong clinical results.
·7 t sittenThe large figures for this stock presuppose that some of the customers succeed with their medicines. It was the uncertainty that DnB pointed out in an earlier analysis and probably then set a criticized price target of 3.5kr when the stock was almost 5kr. The company itself points to this inherent uncertainty in its report now and that is obviously outside the company's control. Has anyone looked into how various customers are progressing with their medicines and the probability that they will succeed?
Rule of thumb is probably about 1/10 succeeds...Little scared by scenario of no approvals..They communicated well in the report, completely in line with guidance, Expansion and scalable prod are in the cards. Yes, the piggy bank could have been bigger, but it costs to start up. Full confidence in the board and management as they guide further for next year. This will be good eventually👍
·7 t sittenWas this as expected, you who are long?
Well, perhaps I didn't expect such a violent reaction, possibly a lot of stop-losses triggered there, yes. Too bad for those who lost money in panic selling, but look forward, is this the highest thor will ever be worth? I think we've just started and this was a dream scenario when the issuance was at 2.5kr. Well done and congratulations to those who secured profit, because that's why we're here, my condolences to those who stressed out and sold at a loss, good weekend🍻
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 H1 -tulosraportti
UUTTA
Tänään
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sitten · MuokattuYes, the market showed where things stand today. As I wrote today before open. It will be red. 11.5 % down indicates that some big players took profit. Some support levels broke down today. Selling pressure was high today. Unfortunately, management didn't have much to offer. Thor must deliver concrete, quantified new large contracts. No input on growth and how the Alpha One factory is functioning. It seemed between the lines that it had slowed down a bit. Management itself says it will generate revenue just under kr 180 million next year. Then it obviously takes far too long to produce Th 228. The market has also reacted to this. The ship MS Thor must get on track and gain more momentum. They should scale up much faster. Then they will get applause from the crew. Thor must switch to faster engines. 💪
- ·6 t sittenReported 6 flat yesterday. Too bad to see I missed by one øre. Ready to go up again to 7 during next week :-)Conclusion from today's H1: : The earnings presentation confirms that Thor has succeeded with the critical step from pilot to industrial production. This is a solid operational result in a company that is still in an early commercialization phase. Current financial figures are weak (as expected since before startup), and the focus going forward will be on actual volume ramp-up, deliveries and cash flow towards break-even in 2027. For investors with high risk appetite within medicine, this is a positive step, but the stock will likely remain volatile until revenues become more visible.
- ·7 t sittenIt's important to note that much of the biotech sector is down today. Not only Thor. Short-term noise.6 t sittenThe Pb-212 market is one of the fastest-growing segments in the entire radiopharmaceutical industry. It is growing at a CAGR of 21.45%, with the market projected to rise from $218 million to $851 million by 2032. Growth is driven by the expansion of TAT therapies, the scaling of Th-228 generators, and strong clinical results.
- ·7 t sittenThe large figures for this stock presuppose that some of the customers succeed with their medicines. It was the uncertainty that DnB pointed out in an earlier analysis and probably then set a criticized price target of 3.5kr when the stock was almost 5kr. The company itself points to this inherent uncertainty in its report now and that is obviously outside the company's control. Has anyone looked into how various customers are progressing with their medicines and the probability that they will succeed?Rule of thumb is probably about 1/10 succeeds...Little scared by scenario of no approvals..They communicated well in the report, completely in line with guidance, Expansion and scalable prod are in the cards. Yes, the piggy bank could have been bigger, but it costs to start up. Full confidence in the board and management as they guide further for next year. This will be good eventually👍
- ·7 t sittenWas this as expected, you who are long?Well, perhaps I didn't expect such a violent reaction, possibly a lot of stop-losses triggered there, yes. Too bad for those who lost money in panic selling, but look forward, is this the highest thor will ever be worth? I think we've just started and this was a dream scenario when the issuance was at 2.5kr. Well done and congratulations to those who secured profit, because that's why we're here, my condolences to those who stressed out and sold at a loss, good weekend🍻
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
2026 H1 -tulosraportti
UUTTA
Tänään
‧45 min
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: Quartr| Seuraava tapahtuma | |
|---|---|
2026 H2 -tulosraportti 26.2.2027 |
| Menneet tapahtumat | ||
|---|---|---|
2026 H1 -tulosraportti 28.8. | ||
2025 H2 -tulosraportti 26.2. | ||
2025 H1 -tulosraportti 29.8.2025 | ||
2024 H2 -tulosraportti 26.2.2025 | ||
2024 H1 -tulosraportti 30.8.2024 |
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·5 t sitten · MuokattuYes, the market showed where things stand today. As I wrote today before open. It will be red. 11.5 % down indicates that some big players took profit. Some support levels broke down today. Selling pressure was high today. Unfortunately, management didn't have much to offer. Thor must deliver concrete, quantified new large contracts. No input on growth and how the Alpha One factory is functioning. It seemed between the lines that it had slowed down a bit. Management itself says it will generate revenue just under kr 180 million next year. Then it obviously takes far too long to produce Th 228. The market has also reacted to this. The ship MS Thor must get on track and gain more momentum. They should scale up much faster. Then they will get applause from the crew. Thor must switch to faster engines. 💪
- ·6 t sittenReported 6 flat yesterday. Too bad to see I missed by one øre. Ready to go up again to 7 during next week :-)Conclusion from today's H1: : The earnings presentation confirms that Thor has succeeded with the critical step from pilot to industrial production. This is a solid operational result in a company that is still in an early commercialization phase. Current financial figures are weak (as expected since before startup), and the focus going forward will be on actual volume ramp-up, deliveries and cash flow towards break-even in 2027. For investors with high risk appetite within medicine, this is a positive step, but the stock will likely remain volatile until revenues become more visible.
- ·7 t sittenIt's important to note that much of the biotech sector is down today. Not only Thor. Short-term noise.6 t sittenThe Pb-212 market is one of the fastest-growing segments in the entire radiopharmaceutical industry. It is growing at a CAGR of 21.45%, with the market projected to rise from $218 million to $851 million by 2032. Growth is driven by the expansion of TAT therapies, the scaling of Th-228 generators, and strong clinical results.
- ·7 t sittenThe large figures for this stock presuppose that some of the customers succeed with their medicines. It was the uncertainty that DnB pointed out in an earlier analysis and probably then set a criticized price target of 3.5kr when the stock was almost 5kr. The company itself points to this inherent uncertainty in its report now and that is obviously outside the company's control. Has anyone looked into how various customers are progressing with their medicines and the probability that they will succeed?Rule of thumb is probably about 1/10 succeeds...Little scared by scenario of no approvals..They communicated well in the report, completely in line with guidance, Expansion and scalable prod are in the cards. Yes, the piggy bank could have been bigger, but it costs to start up. Full confidence in the board and management as they guide further for next year. This will be good eventually👍
- ·7 t sittenWas this as expected, you who are long?Well, perhaps I didn't expect such a violent reaction, possibly a lot of stop-losses triggered there, yes. Too bad for those who lost money in panic selling, but look forward, is this the highest thor will ever be worth? I think we've just started and this was a dream scenario when the issuance was at 2.5kr. Well done and congratulations to those who secured profit, because that's why we're here, my condolences to those who stressed out and sold at a loss, good weekend🍻
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt